Factors influencing the natural history of HIV-1 infection

Chinese Medical Journal

Volumn 121, Issue 24, 2008, Pages 2613-2621

  Qu, Wei ^a   Robinson, Matthew ^b   Zhang, Fu Jie ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

HIV infections; Influencing factors; Natural history

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA B57 ANTIGEN; HLA DR1 ANTIGEN; HLA DR11 ANTIGEN; HLA DR5 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; NEF PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIF PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CHINA; DEATH; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; EPIDEMIC; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHY; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LYMPHOCYTE COUNT; MALARIA; MIXED INFECTION; NONHUMAN; PATIENT COMPLIANCE; RISK FACTOR; SEROCONVERSION; SOCIOECONOMICS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 60649117391     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200812020-00026     Document Type: Article

References (92)

1. Bartlett JG, Gallant JE. Medical management of HIV infection. In: Johns Hopkins Medicine Health Publishing Business Group, Baltimore, Maryland; 2007: 1.
2. Soogoor M, Daar ES. Primary HIV-1 infection: diagnosis, pathogenesis, and treatment. Curr Infect Dis Rep 2005; 7: 147-153.
3. Saksena NK, Rodes B, Wang B, Soriano V. Elite HIV controllers: myth-or reality? AIDS Rev 2007; 9: 195-207.
4. Deeks SG, Waiker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy, Immunity 2007; 27: 406-416.
5. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North Am 2000; 14: 809-825, v-vi.
6. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42: 709-715.
7. Lavreys L, Baeten JM, Chohan V, MeClelland RS, Hassan WM, Richardson BA, et al. Higher set point plasma viral load and more-severe acute HIV type 1. (HIV-1) illness predict mortality among high-risk H1V-1-infected African women. Clin Infect Dis 2006; 42: 1333-1339.
8. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 29, 2008. (Aceessed at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.)
9. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
10. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296: 1498-1506.
11. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in mitreated HIV-1 infection. JAMA 2007; 297: 2349-2350.
12. Blattner WA, Oursler KA, Cleghorn F, Charurat M, Sill A, Bartholomew C, et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004; 189: 1793-1801.
13. Gilks C, Vitória M. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Inc. WHO; 2006.
14. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355: 1131-1137.
15. Isingo R, Zaba B, Marston M, Ndege M, Mngara J, Mwita W, et al. Survival after HIV infection in the pre-antiretroviral therapy era in a rural Tanzanian cohort. AIDS 2007; 21 Suppl 6: s5-s13.
16. Van der Paal L, Shafer LA, Todd J, Mayanja BN, Whitworth JA, Grosskurth H. HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda. AIDS 2007; 21 Suppl 6: s21-s29.
17. Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, et al. Survival of HIV-infeeted treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007; 21 Suppl 6: s15-s19.
18. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, Mwita W, et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 2007; 21 Suppl 6: s55-s63.
19. The eligibility for ART in lower income countries (eART-linc) collaboration. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008; 84 Suppl 1: i31-i36.
20. Zhang F, Dou Z. An ambispective cohort study of the natural history of HIV infection among former unsafe commercial blood and plasma donors. Chin J Epidemiol (Chin) 2008; 1: 9-12.
21. Fan L, Zhang LF, Wang Z, Qiao XC. A retrospective cohort study on the natural history of human immunodeficiency virus among formal plasma donors in central China. Chin J Epidemiol (Chin) 2005; 26: 311-313.
22. Zheng X. The natural history of HIV infection among IDUs in Ruili, Yunnan Province, China. Chin J Epidemiol (Chin) 2000; 21: 17-18.
23. Martinez-Steele E, Awasana AA, Corrah T, Sabally S, van der Sande M, Jaye A, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21: 317-324.
24. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197: 707-713.
25. Shao Y, Xing H, Hong K, Feng Y, Chen J, Shang H, et al. National HIV gene variation and traasmission characteristics research database construction. In: China Awards for Science and Technology, 200601079; 2006.
26. Gorry PR, Churchill M, Learmont J, Cherry C, Dyer WB, Wesselingh SL, et al. Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo. J Acquir Immune Defic Syndr 2007; 46: 390-394.
27. Kondo M, Shima T, Nishizawa M, Sudo K, Iwamuro S, Okabe T, et al. Identification of attenuated variants of HIV-1 circulating recombinant form 01Æ that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences. J Infect Dis 2005; 192: 56-561.
28. Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, et al. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type I containing deletions in the nef and long terminal repeat regions. J Virol 2007; 81: 9268-9278.
29. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45: 643-649.
30. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, Piazza P, et al. Emergence and Persistence of CXCR4-Tropic HIV-1 in a Population of Men from the Multicenter AIDS Cohort Study. J Infect Dis 2008; 198: 1104-1112.
31. Guo YF, Ma LY, Yuan L, Wang SH, Sun JP, Xu WS, et al. R5 to X4 coreceptor switch of human immunodeficiency virus type 1 B' and B'/C recombinant subtype isolates in China. Chin Med J 2007; 120: 522-525.
32. Glynn JR, Sonnenborg P, Nelson G, Bester A, Shearer S, Murray J. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort: study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007; 21: 625-632.
33. Kitchen M, Quigley MA, Mwinga AM, Fuchs D, Lisse IM, Porter JD, et al. HIV progression and predictors of mortality in a community-based cohort of Zambian adults. J Int Assoc Physicians AIDS Care (Chic III) 2008; 7: 17-26.
34. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684-691.
35. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22: 1463-1473.
36. A joint assessment of HIV/AIDS prevention, treatment and care in China. In: State Council AIDS Working Committee Office UN Theme Group on AIDS. China; 2007: 3.
37. UNAIDS. Report on the global AIDS epidemic. 2008: 37-38. (Accessed November 28, 2008 at http://www.unaids/org/en/KnowledgeCentre/HIVData/ GlobalReport/2008/2008_Global_report.asp)
38. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364: 1236-1243.
39. Gisselquist D, Potterat JJ, Brody S. HIV transmission during paediatric health care in sub-Saharan Africa - risks and evidence. S Afr Med J 2004; 94: 109-116.
40. Espinoza L, Hall HI, Selik RM, Hu X. Characteristics of HIV infection among hispanics, United States 2003-2006. J Acquir Immune Defic Syndr 2008; 49: 94-101.
41. Little K, Newell ML, Luo C, Ngongo N, Borja MC, McDermott P. Estimating the number of vertically HIV-infected children eligible for antiretroviral treatment in resource-limited settings. Int J Epidemiol 2007; 36: 679-687.
42. Chopra M, Rollins N. Infant feeding in the time of HIV: rapid assessment of infant feeding policy and programmes in four African countries scaling up prevention of mother to child transmission programmes. Arch Dis Child 2008; 93. 288-2891.
43. Rajasekaran S, Jeyaseelan L, Ravichandran N, Gomathi C, Thara F, Chandrasekar C. Efficacy of antiretroviral therapy program in children in India: prognostic factors and survival analysis. J Trop Pediatr 2008.
44. Cohen M. Natural history of HIV infection in women. Obstet Gynecol Clin North Am 1997; 24: 743-758.
45. Anastos K, Denenberg R, Solomon L. Human immunodeficiency virus infection in women. Med Clin North Am 1997;81: 533-553.
46. Belden KA, Squires KE. HIV infection in women: do sex and gender matter? Curr Infect Dis Rep 2008; 10: 423-431.
47. Gilad J, Walfisch A, Borer A, Schlaeffer F. Gender differences and sex-specific manifestations associated with human immunodeficiency virus infection in women. Eur J Obstet Gynecol Reprod Biol 2003; 109: 199-205.
48. Spijkerman IJ, Langendam MW, Veugelers PJ, van Ameijden EJ, Keet IP, Geskus RB, et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996; 7: 571-577.
49. Carre N, Prins M, Meyer L, Brettle RP, Robertson McAxdle H, et al. Has the rate of progression to AIDS changed in recent years? AIDS 1997; 11: 1611-1618.
50. Vittinghoff E, Hessol NA, Bacchetti P, Fusaro RE, Holmberg SD, Buchbinder SP. Cofactors for HIV disease progression in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr 2001; 27: 308-314.
51. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997; 11: 621-631.
52. Yan J, Zheng X, Zhang X, Liu S, Zhang Y, Wang C, et al. The survey of prevalence of HIV infection among paid blood donors in one county in China. Chin J Epidemiol (Chin) 2000; 21: 17-19.
53. Kilmarx PH, Limpakarnjanarat K, Kaewkungwal J, Srismith R, Saisorn S, Utha W, et al. Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 2000; 181: 1598-1606.
54. Anzala OA, Nagelkerke NJ, Bwayo JJ, Holton D, Moses S, Ngugi EN, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995; 171: 686-689.
55. Hayes CG, Manaloto CR, Basaca-Sevilla V, Padre LP, Laughlin LW, O'Rourke TF, et al. Epidemiology of HIV infection among prostitutes in the Philippines. J Acquir Immune Defic Syndr 1990; 3: 913-920.
56. Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, et al. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok Thailand, Int J Epidemiol 1998; 27: 289-295.
57. Volkow P, Velasco SR, Mueller N, de Leon S Ponce, Sierra-Madero JG, Sada E, et al. Transfusion-associated HIV infection in Mexico-related to paid blood donors, HIV epidemic. Int J STD AIDS 2004; 15 337-342.
58. Burton DR. Antibodies viruses and vaccines: Nat Rev Immuno1 2002; 2: 706-713.
59. Wang Q, Shang H, Hall X, et al. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors. Microbiol Immunol 2008; 52:209-215.
60. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003; 26: 121-132.
61. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007; 14: 1325-1334.
62. Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. HIV Med 2007; 8: 213-219.
63. Vilades C, Broch M, Plana M, et al. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresefited in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 2007; 44: 132-138.
64. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008; 5: 51-66.
65. Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, Coulonges C, et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005; 191: 159-163.
66. Dezube BJ, Lederman MM, Chapman B, Georges DL, Dogon AL, Mudido P, et al. The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis 1997; 176: 807-810.
67. Wig N, Anupama P, Singh S, Handa R, Aggarwal P, Dwivedi SN, et al. Tumor necrosis factor-alpha levels in patients with HIV with wasting in South Asia. AIDS Patient Care STDS 2005; 19: 212-215.
68. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756.
69. Equils O, Shapiro A, Madak Z, Liu C, Lu D. Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. Antimicrob Agents Chemother 2004; 48: 3905-3911.
70. Khoo SH, Pepper L, Snowden N, Hajee AH, Vallely P, Wilkins EG, et al. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997; 11: 423-428.
71. Tomiyama H, Fujiwara M, Oka S, Takiguchi M. Cutting edge: epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J Immunol 2005; 174: 36-40.
72. Nolan D, Gaudieri S, John M, Mallal S. Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground. AIDS 2004; 18 1231 -1240.
73. Kaslow RA, Rivers C, Tang J, Bender TJ, Goepfert PA, Habib RE, et. al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox Vaccines. J Virol 2001; 75: 8181-8689.
74. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344: 1668-1675.
75. Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, et al. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis 1999; 180: 299-309.
76. van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology 2007; 4: 67-78.
77. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008; 23: 1000-1008.
78. Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42: 1481-1487.
79. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32: 33-46.
80. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22: 1399-1410.
81. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-year old. Chin J Epidemiol (Chin) 2005; 26: 655-658.
82. Wang YC, Xu SH, Li XH, Song AJ, Jia XR, Zhuang H. A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users. Chin J Epidemiol (Chin) 2006; 27: 777-779.
83. Li JR, Gong RY, Tian KL, Wang J, Wang YX, Huang HJ. Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users. World J Gastroenterol 2007; 13: 2357-2362.
84. Xu JQ, Wang JJ, Han LF, Xu C, Ruan YH, Xu ZH, et al. Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J 2006; 119: 1941-1948.
85. Sulkowski MS. Vital hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367.
86. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte A d'Arminio, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
87. Yu A, Berbari E, Temesgen Z. Antiretroviral therapy in HIV. J Med Liban 2006; 54: 74-79.
88. Panos G, Samonis G, Alexiou VG, Kavamou GA, Charatsis G, Falagas ME. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res 2008; 6: 257-260.
89. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART mitiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses 2007; 23: 1338-1347.
90. Puvimanasinghe JPA, Ndwapi N, Gaolathe T, Musuka Manthe L, Moeti T, et al. Six years of HAART in the public sector of Botswana. Seventeenth International AIDS Conference: Mexico City, 2008. (Accessed November 28, 2008 at http://www.aids2008.org/Pag/Abstracts.aspx?SID=223&AID= 10814)
91. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral theraphy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008; 47: 825-833.
92. Hartzell JD, Janke IE, Weintrob AC. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008; 62: 246-255.